{"id":5253,"date":"2019-06-13T12:14:32","date_gmt":"2019-06-13T06:44:32","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=5253"},"modified":"2021-07-24T12:57:24","modified_gmt":"2021-07-24T07:27:24","slug":"the-business-cocktail-adc-therapeutics","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-adc-therapeutics","title":{"rendered":"Telegenomics nets $23M; Merck acquires Tilos; ADC nabs; Sobi buys Novoimmune&#8217;s assets"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-6a3f5f7f2de40\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-6a3f5f7f2de40\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-4'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-adc-therapeutics\/#Telegenomics_Company_Genome_Medical_nets_USD_23_M\" >Telegenomics Company Genome Medical nets USD 23 M<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-4'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-adc-therapeutics\/#Merck_acquires_Tilos_for_USD_773_M\" >Merck acquires Tilos for USD 773 M<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-4'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-adc-therapeutics\/#ADC_nabs_USD_76_M_in_a_series_E_funding\" >ADC nabs USD 76 M in a series E funding<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-4'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-adc-therapeutics\/#Sobi_buys_Novoimmune_R_D_assets\" >Sobi buys Novoimmune R&amp;D assets<\/a><\/li><\/ul><\/nav><\/div>\n\n<h4 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Telegenomics_Company_Genome_Medical_nets_USD_23_M\"><\/span><strong>Telegenomics Company Genome Medical nets USD 23 M<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h4>\n\n\n\n<p><strong>Genome Medical<\/strong>, a telegenomics company, having expertise in delivering genome-based medicine has raised <strong>USD 23 Million<\/strong> in series B funding. &nbsp;The proceeds will be used by the company to accelerate the development of its technology and medical services to support patients, physicians and healthcare systems. The financing was led by Echo Health Ventures, a strategic collaboration of Cambia Health Solutions and Mosaic Health Solutions. The company is confident of meeting the rising demand for genetic services along with education, consent, pre-test genetic counselling, etc. with the help of proceeds. <\/p>\n\n\n\n<h4 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Merck_acquires_Tilos_for_USD_773_M\"><\/span><strong>Merck acquires Tilos for USD 773 M <\/strong><span class=\"ez-toc-section-end\"><\/span><\/h4>\n\n\n\n<p><strong>Merck Therapeutics<\/strong> has signed an agreement to buy a private biopharma company <strong>Tilos Therapeutics<\/strong> for up to <strong>USD 773 Million.<\/strong> The news came after a month of Merck acquiring oncology drug developer- <strong>Peloton Therapeutics, <\/strong>for USD 105 billion. Tilos, founded in 2016, has been focusing on developing an array of antibodies that target LAP \u2013 a protein that forms a cage around TGF-beta and keeps the cytokine inactive until it is deployed. The acquiring of Tilos will give Merck an exposure into TGF-beta- anti-LAP antibodies, aiming to offer patients struggling with <a href=\"https:\/\/www.delveinsight.com\/report-store\/non-small-cell-lung-cancer-market\">cancer<\/a>, <strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/idiopathic-pulmonary-fibrosis-market-insight-epidemiology-and-market-forecast\">fibrosis <\/a><\/strong>and autoimmune diseases an effective therapy.<\/p>\n\n\n\n<h4 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"ADC_nabs_USD_76_M_in_a_series_E_funding\"><\/span><strong>ADC nabs USD 76 M in a series E funding <\/strong><span class=\"ez-toc-section-end\"><\/span><\/h4>\n\n\n\n<p><strong>ADC Therapeutics<\/strong> has closed a <strong>USD 76 million<\/strong> expansion of its Series E financing raising its total proceeds to USD 276 million.&nbsp; The company, since its commencement in 2011, has successfully raised USD 531 million. The proceeds will be used to enhance the development of pyrrolobenzodiazepine (PBD)-based ADCs for the treatment of haematological cancer and solid tumors. ADC Therapeutics also plans to successfully run the Phase II clinical trial of ADCT-402 and ADCT-301 in patients with <strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/hodgkins-lymphoma-hl-market\">Hodgkin <\/a><\/strong>and <strong>non-Hodgkin lymphomas<\/strong> and solid tumors.<\/p>\n\n\n\n<h4 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Sobi_buys_Novoimmune_R_D_assets\"><\/span><strong>Sobi buys Novoimmune R&amp;D assets <\/strong><span class=\"ez-toc-section-end\"><\/span><\/h4>\n\n\n\n<p><strong>Sobi<\/strong>, a Swedish rare disease company dedicated to providing access to innovative treatments in rare diseases, today announced the acquisition of immunology R&amp;D capabilities from <strong>Novimmune <\/strong>including emapalumab and related assets for<strong> USD 518 Million<\/strong>. Sobi\u2019s lead drug candidates and therapy pipeline are already dominated by pre-clinical trials in Immunology and Hematology. However, through this acquisition, the company plans to shift its focus to late-stage assets for the same by divesting SOBI003 and preclinical program SOBI006. Also, the company plans to lay the foundation of its new centres in Sweden and Switzerland, where Novoimmune is based. <\/p>\n","protected":false},"excerpt":{"rendered":"<p>Telegenomics Company Genome Medical nets USD 23 M Genome Medical, a telegenomics company, having expertise in delivering genome-based medicine has raised USD 23 Million in series B funding. &nbsp;The proceeds will be used by the company to accelerate the development of its technology and medical services to support patients, physicians and healthcare systems. The financing [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":5221,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[60,4522,395,683,17726,542,17725],"industry":[17225],"therapeutic_areas":[],"class_list":["post-5253","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-adc","tag-genome-medical","tag-merck","tag-mergers-and-acquisitions","tag-novoimmune","tag-sobi","tag-telegenomics","industry-pharmaceutical"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Telegenomics nets $23M; Merck acquires Tilos; ADC nabs<\/title>\n<meta name=\"description\" content=\"ADC Therapeutics has closed a USD 76 million expansion of its Series E financing raising its total proceeds to USD 276 million...\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-adc-therapeutics\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Telegenomics nets $23M; Merck acquires Tilos; ADC nabs\" \/>\n<meta property=\"og:description\" content=\"ADC Therapeutics has closed a USD 76 million expansion of its Series E financing raising its total proceeds to USD 276 million...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-adc-therapeutics\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2019-06-13T06:44:32+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-07-24T07:27:24+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/06\/09021809\/Business-6-JUNE.png\" \/>\n\t<meta property=\"og:image:width\" content=\"750\" \/>\n\t<meta property=\"og:image:height\" content=\"410\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Telegenomics nets $23M; Merck acquires Tilos; ADC nabs","description":"ADC Therapeutics has closed a USD 76 million expansion of its Series E financing raising its total proceeds to USD 276 million...","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-adc-therapeutics","og_locale":"en_US","og_type":"article","og_title":"Telegenomics nets $23M; Merck acquires Tilos; ADC nabs","og_description":"ADC Therapeutics has closed a USD 76 million expansion of its Series E financing raising its total proceeds to USD 276 million...","og_url":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-adc-therapeutics","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2019-06-13T06:44:32+00:00","article_modified_time":"2021-07-24T07:27:24+00:00","og_image":[{"width":750,"height":410,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/06\/09021809\/Business-6-JUNE.png","type":"image\/png"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-adc-therapeutics","url":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-adc-therapeutics","name":"Telegenomics nets $23M; Merck acquires Tilos; ADC nabs","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-adc-therapeutics#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-adc-therapeutics#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/06\/09021809\/Business-6-JUNE.png","datePublished":"2019-06-13T06:44:32+00:00","dateModified":"2021-07-24T07:27:24+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"ADC Therapeutics has closed a USD 76 million expansion of its Series E financing raising its total proceeds to USD 276 million...","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-adc-therapeutics"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-adc-therapeutics#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/06\/09021809\/Business-6-JUNE.png","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/06\/09021809\/Business-6-JUNE.png","width":750,"height":410,"caption":"The Business cocktail"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/06\/09021809\/Business-6-JUNE-300x164.png","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">ADC<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Genome Medical<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Merck<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Mergers and Acquisitions<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Novoimmune<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Sobi<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Telegenomics<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">ADC<\/span>","<span class=\"advgb-post-tax-term\">Genome Medical<\/span>","<span class=\"advgb-post-tax-term\">Merck<\/span>","<span class=\"advgb-post-tax-term\">Mergers and Acquisitions<\/span>","<span class=\"advgb-post-tax-term\">Novoimmune<\/span>","<span class=\"advgb-post-tax-term\">Sobi<\/span>","<span class=\"advgb-post-tax-term\">Telegenomics<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 7 years ago","modified":"Updated 5 years ago"},"absolute_dates":{"created":"Posted on Jun 13, 2019","modified":"Updated on Jul 24, 2021"},"absolute_dates_time":{"created":"Posted on Jun 13, 2019 12:14 pm","modified":"Updated on Jul 24, 2021 12:57 pm"},"featured_img_caption":"The Business cocktail ","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/5253","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=5253"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/5253\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/5221"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=5253"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=5253"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=5253"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=5253"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=5253"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}